Terms: = Skin cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
27 results:
1. Association of genetic polymorphisms of CYP3A4 and cyp2d6 with gefitinib-induced toxicities.
Kwok WC; Lam DCL; Ip MSM; Tam TCC; Ho JCM
Anticancer Drugs; 2022 Nov; 33(10):1139-1144. PubMed ID: 35946566
[TBL] [Abstract] [Full Text] [Related]
2. Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians.
Wang CW; Tassaneeyakul W; Chen CB; Chen WT; Teng YC; Huang CY; Sukasem C; Lu CW; Lee YS; Choon SE; Nakkam N; Hui RC; Huang YH; Chang YC; Lin YY; Chang CJ; Chiu TM; Chantratita W; Konyoung P; Lee CN; Klaewsongkram J; Rerkpattanapipat T; Amornpinyo W; Saksit N; Rerknimitr P; Huang YH; Lin SH; Hsu CK; Chan CC; Lin YJ; Hung SI; Chung WH;
J Allergy Clin Immunol; 2021 Apr; 147(4):1402-1412. PubMed ID: 32791162
[TBL] [Abstract] [Full Text] [Related]
3. Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailments.
Tandon N; Yadav SS
J Ethnopharmacol; 2020 Jun; 255():112768. PubMed ID: 32201301
[TBL] [Abstract] [Full Text] [Related]
4. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
[TBL] [Abstract] [Full Text] [Related]
5. Effects of polymorphisms in cyp2d6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.
Kobayashi H; Sato K; Niioka T; Takeda M; Okuda Y; Asano M; Ito H; Miura M
Med Oncol; 2016 Jun; 33(6):57. PubMed ID: 27154635
[TBL] [Abstract] [Full Text] [Related]
6. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Hirose T; Fujita K; Kusumoto S; Oki Y; Murata Y; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ohmori T; Sasaki Y
Lung Cancer; 2016 Mar; 93():69-76. PubMed ID: 26898617
[TBL] [Abstract] [Full Text] [Related]
7. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
Sun B; Liu K; Han J; Zhao LY; Su X; Lin B; Zhao DM; Cheng MS
Bioorg Med Chem; 2015 Oct; 23(20):6763-73. PubMed ID: 26365710
[TBL] [Abstract] [Full Text] [Related]
8. Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung cancer.
Kobayashi H; Sato K; Niioka T; Miura H; Ito H; Miura M
Clin Lung Cancer; 2015 Jul; 16(4):274-81. PubMed ID: 25554506
[TBL] [Abstract] [Full Text] [Related]
9. Gefitinib.
Rahman AF; Korashy HM; Kassem MG
Profiles Drug Subst Excip Relat Methodol; 2014; 39():239-64. PubMed ID: 24794908
[TBL] [Abstract] [Full Text] [Related]
10. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
[TBL] [Abstract] [Full Text] [Related]
11. Genetics in melanoma.
Stahl S; Bar-Meir E; Friedman E; Regev E; Orenstein A; Winkler E
Isr Med Assoc J; 2004 Dec; 6(12):774-7. PubMed ID: 15609895
[TBL] [Abstract] [Full Text] [Related]
12. Combined effects of gender, skin type and polymorphic genes on clinical phenotype: use of rate of increase in numbers of basal cell carcinomas as a model system.
Ramachandran S; Fryer AA; Lovatt TJ; Smith AG; Lear JT; Jones PW; Strange RC
Cancer Lett; 2003 Jan; 189(2):175-81. PubMed ID: 12490310
[TBL] [Abstract] [Full Text] [Related]
13. Genetic factors determining cutaneous basal cell carcinoma phenotype.
Ramachandran S; Fryer AA; Strange RC
Med Pediatr Oncol; 2001 May; 36(5):559-63. PubMed ID: 11340612
[TBL] [Abstract] [Full Text] [Related]
14. Basal cell carcinomas: association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype.
Ramachandran S; Fryer AA; Smith AG; Lear JT; Bowers B; Hartland AJ; Whiteside JR; Jones PW; Strange RC
Pharmacogenetics; 2001 Apr; 11(3):247-54. PubMed ID: 11337940
[TBL] [Abstract] [Full Text] [Related]
15. Glutathione S-transferase GSTP1 and cyclin D1 genotypes: association with numbers of basal cell carcinomas in a patient subgroup at high-risk of multiple tumours.
Ramachandran S; Hoban PR; Ichii-Jones F; Pleasants L; Ali-Osman F; Lear JT; Smith AG; Bowers B; Jones PW; Fryer AA; Strange RC
Pharmacogenetics; 2000 Aug; 10(6):545-56. PubMed ID: 10975609
[TBL] [Abstract] [Full Text] [Related]
16. Cytochrome P450 cyp2d6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma.
Strange RC; Ellison T; Ichii-Jones F; Bath J; Hoban P; Lear JT; Smith AG; Hutchinson PE; Osborne J; Bowers B; Jones PW; Fryer AA
Pharmacogenetics; 1999 Jun; 9(3):269-76. PubMed ID: 10471058
[TBL] [Abstract] [Full Text] [Related]
17. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci.
Clairmont A; Sies H; Ramachandran S; Lear JT; Smith AG; Bowers B; Jones PW; Fryer AA; Strange RC
Carcinogenesis; 1999 Jul; 20(7):1235-40. PubMed ID: 10383895
[TBL] [Abstract] [Full Text] [Related]
18. Polymorphism in cytochrome P450 cyp2d6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers.
Matthias C; Bockmühl U; Jahnke V; Jones PW; Hayes JD; Alldersea J; Gilford J; Bailey L; Bath J; Worrall SF; Hand P; Fryer AA; Strange RC
Pharmacogenetics; 1998 Apr; 8(2):91-100. PubMed ID: 10022746
[TBL] [Abstract] [Full Text] [Related]
19. Presentation with multiple cutaneous basal cell carcinomas: association of glutathione S-transferase and cytochrome P450 genotypes with clinical phenotype.
Ramachandran S; Lear JT; Ramsay H; Smith AG; Bowers B; Hutchinson PE; Jones PW; Fryer AA; Strange RC
Cancer Epidemiol Biomarkers Prev; 1999 Jan; 8(1):61-7. PubMed ID: 9950241
[TBL] [Abstract] [Full Text] [Related]
20. Polymorphism in glutathione S-transferase loci as a risk factor for common cancers.
Strange RC; Lear JT; Fryer AA
Arch Toxicol Suppl; 1998; 20():419-28. PubMed ID: 9442313
[TBL] [Abstract] [Full Text] [Related]
[Next]
